Gabelli Funds’s Charles River Laboratories CRL Stock Holding History

Gabelli Funds’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$386K	Hold	1,700	–	–	﹤0.01%	1101
2026 Q1	$293K	Hold	1,700	–	–	﹤0.01%	1116
2025 Q4	$339K	Sell	1,700 -16,800	-91%	-$3.05M	﹤0.01%	1095
2025 Q3	$2.89M	Sell	18,500 -1,000	-5%	-$159K	0.02%	646
2025 Q2	$2.96M	Hold	19,500	–	–	0.02%	639
2025 Q1	$2.94M	Hold	19,500	–	–	0.02%	572
2024 Q4	$3.6M	Sell	19,500 -700	-3%	-$135K	0.03%	521
2024 Q3	$3.98M	Hold	20,200	–	–	0.03%	509
2024 Q2	$4.17M	Hold	20,200	–	–	0.03%	484
2024 Q1	$5.47M	Hold	20,200	–	–	0.04%	431
2023 Q4	$4.78M	Hold	20,200	–	–	0.04%	455
2023 Q3	$3.96M	Hold	20,200	–	–	0.03%	487
2023 Q2	$4.25M	Hold	20,200	–	–	0.03%	493
2023 Q1	$4.08M	Hold	20,200	–	–	0.03%	500
2022 Q4	$4.4M	Sell	20,200 -765	-4%	-$167K	0.03%	485
2022 Q3	$4.13M	Sell	20,965 -3,735	-15%	-$806K	0.03%	488
2022 Q2	$5.29M	Buy	24,700 +12,200	+98%	+$2.98M	0.04%	453
2022 Q1	$3.55M	Buy	12,500 +7,000	+127%	+$2.16M	0.02%	590
2021 Q4	$2.07M	Hold	5,500	–	–	0.01%	728
2021 Q3	$2.27M	Sell	5,500 -13,750	-71%	-$5.71M	0.02%	704
2021 Q2	$7.12M	Sell	19,250 -2,861	-13%	-$955K	0.05%	431
2021 Q1	$6.41M	Sell	22,111 -7,000	-24%	-$1.95M	0.04%	445
2020 Q4	$7.27M	Hold	29,111	–	–	0.05%	390
2020 Q3	$6.59M	Sell	29,111 -1,750	-6%	-$363K	0.05%	385
2020 Q2	$5.38M	Hold	30,861	–	–	0.04%	420
2020 Q1	$3.9M	Sell	30,861 -5,000	-14%	-$750K	0.03%	468
2019 Q4	$5.48M	Buy	35,861 +2,750	+8%	+$381K	0.04%	480
2019 Q3	$4.38M	Buy	33,111 +4,111	+14%	+$551K	0.03%	548
2019 Q2	$4.12M	Buy	29,000 +2,500	+9%	+$339K	0.03%	589
2019 Q1	$3.85M	Sell	26,500 -500	-2%	-$65.7K	0.02%	607
2018 Q4	$3.06M	Sell	27,000 -5,000	-16%	-$626K	0.02%	638
2018 Q3	$4.3M	Sell	32,000 -10,000	-24%	-$1.23M	0.02%	613
2018 Q2	$4.71M	Buy	42,000 +15,000	+56%	+$1.62M	0.03%	578
2018 Q1	$2.88M	Buy	27,000 +2,946	+12%	+$318K	0.02%	690
2017 Q4	$2.63M	Buy	24,054 +10,554	+78%	+$1.15M	0.02%	719
2017 Q3	$1.46M	Hold	13,500	–	–	0.01%	845
2017 Q2	$1.37M	Sell	13,500 -13,500	-50%	-$1.24M	0.01%	851
2017 Q1	$2.43M	Sell	27,000 -10,000	-27%	-$849K	0.01%	732
2016 Q4	$2.82M	Hold	37,000	–	–	0.02%	706
2016 Q3	$3.08M	Hold	37,000	–	–	0.02%	682
2016 Q2	$3.05M	Buy	37,000 +10,000	+37%	+$824K	0.02%	679
2016 Q1	$2.05M	Buy	+27,000	New	+$2M	0.01%	755

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Gabelli Funds's CRL Position: Q2 2026 in Review

Gabelli Funds held its Charles River Laboratories (CRL) position steady in Q2 2026 at 1,700 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Gabelli Funds first reported a position in CRL in Q1 2016 and has held it in 42 quarters since. The position peaked at $7.27M in Q4 2020. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Gabelli Funds held 1,700 shares of Charles River Laboratories worth $386K as of Q2 2026.
Gabelli Funds left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Gabelli Funds's portfolio in Q2 2026, its #1101 holding.
Gabelli Funds first reported a position in Charles River Laboratories in Q1 2016 and has held it in 42 quarters since.
Gabelli Funds's Charles River Laboratories position peaked at $7.27M in Q4 2020.
565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.